Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
H. Lundbeck A/S (Lundbeck) today announced the appointment of Dianne Hol to the role of EVP, People & Organization. Dianne will join Lundbeck on 1 April 2024 and will be part of the Executive Management.
Dianne will be responsible for driving Lundbeck's people strategy to support its growth journey and assist in developing the organization further. With an impressive international background in HR leadership, Dianne brings a wealth of experience and expertise to Lundbeck. Her track record speaks volumes about her capability to enhance both company and people's performance, while also building high-performing HR teams.
"I look forward to welcoming Dianne to her new position in Lundbeck, says Charl van Zyl; President and CEO of Lundbeck. With her proven track record of driving performance and fostering talent, I'm confident that her leadership will play a crucial role in propelling our company forward."
"I'm excited to be a part of Lundbeck's mission to improve the lives of people living with brain disorders through a clear people strategy which fosters a culture of innovation and where every person can thrive and perform at their best," says Dianne Hol.
Dianne joins Lundbeck from AstraZeneca where she served as Vice President Global Human Resources in different global business areas, latest in BioPharmaceuticals & Japan. Prior to this, she was Global Head of Human Resources Roche Diabetes Care. Dianne is Dutch and holds a Bachelor of Arts Human Resources Management Hogeschool van Utrecht, Netherlands.
Contacts
Thomas Mikkel Mortensen Palle Holm Olesen
Media Relations Lead, Corp. Communication Vice President, Investor Relations
THMR@lundbeck.com PALO@lundbeck.com
+45 30 83 30 24 +45 30 83 24 26
Sophia Nørskov Bech
Senior Manager, Investor Relations
SONQ@lundbeck.com
+45 30 83 24 60
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.
Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
For additional information, we encourage you to visit our corporate site www.lundbeck.com (https://www.lundbeck.com/global) and connect with us via LinkedIn (https://www.linkedin.com/company/lundbeck/).